1
|
Ruan H, Long M, Li J, Zhang D, Feng N, Zhang Y. Sustained-Release Hydrogen-Powered Bilateral Microneedles Integrating CD-MOFs for In Situ Treating Allergic Rhinitis. Adv Healthc Mater 2024:e2400637. [PMID: 38749484 DOI: 10.1002/adhm.202400637] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2024] [Revised: 05/06/2024] [Indexed: 05/23/2024]
Abstract
Glucocorticoids are widely used for treating allergic rhinitis, but conventional intranasal administration encounters unfavorable nasal cilia clearance and nasal mucosal barrier. Herein, a bilateral microneedle patch is fabricated for delivering cyclodextrin-based metal-organic frameworks (CD-MOF) encapsulating dexamethasone (DXMS) and paeonol (Pae), while NaH particles are mounted on the basal part of each microneedle. By intranasal administration, the microneedles are propelled into the nasal mucosa by NaH-generated hydrogen and then swell to form a hydrogel for sustainedly releasing drugs. The DXMS/Pae combination is demonstrated to be superior to more than the twofold dose of DXMS alone for improving allergic rhinitis in rats. It involves reducing mast cell degranulation and modulating Treg/Th17 cell homeostasis, whereas inhibiting Th1 to Th2 differentiation is associated with regulating the GATA3/T-bet pathway, as well as repairing epithelial barrier function by increasing MUC1 and downregulating periostin. In addition, this delivery system modulates the lipid metabolism of the nasal mucosa. Notably, the newly designed device significantly enhances the drug's therapeutic effect, and NaH-generated hydrogen may have the potential adjunctive therapeutic effect. Collectively, such an emerging microneedle-mediated nasal drug delivery creates a new form for alleviating immune inflammation and contributes a promising solution to reduce clinical glucocorticoid abuse.
Collapse
Affiliation(s)
- Hang Ruan
- School of pharmacy, Shanghai University of Traditional Chinese Medicine, No.1200 Cailun Road, Pudong New Area, Shanghai, 201203, China
| | - Meng Long
- School of pharmacy, Shanghai University of Traditional Chinese Medicine, No.1200 Cailun Road, Pudong New Area, Shanghai, 201203, China
| | - Jiaqi Li
- School of pharmacy, Shanghai University of Traditional Chinese Medicine, No.1200 Cailun Road, Pudong New Area, Shanghai, 201203, China
| | - Di Zhang
- School of pharmacy, Shanghai University of Traditional Chinese Medicine, No.1200 Cailun Road, Pudong New Area, Shanghai, 201203, China
| | - Nianping Feng
- School of pharmacy, Shanghai University of Traditional Chinese Medicine, No.1200 Cailun Road, Pudong New Area, Shanghai, 201203, China
| | - Yongtai Zhang
- School of pharmacy, Shanghai University of Traditional Chinese Medicine, No.1200 Cailun Road, Pudong New Area, Shanghai, 201203, China
| |
Collapse
|
2
|
Tao Q, Xu L, Zhang Y, Yang Y, Liu Z, Xu T, Lai S, Ai Y, Zhu L, Xu Z. The construction and immunogenicity analyses of a recombinant pseudorabies virus with Senecavirus A VP3 protein co-expression. Vet Microbiol 2024; 290:110011. [PMID: 38310713 DOI: 10.1016/j.vetmic.2024.110011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2023] [Revised: 01/19/2024] [Accepted: 01/20/2024] [Indexed: 02/06/2024]
Abstract
Senecavirus A (SVA)-associated porcine idiopathic vesicular disease (PIVD) and Pseudorabies (PR) are highly contagious swine disease that pose a significant threat to the global pig industry. In the absence of an effective commercial vaccine, outbreaks caused by SVA have occurred in many parts of the world. In this study, the PRV variant strain PRV-XJ was used as the parental strain to construct a recombinant PRV strain with the TK/gE/gI proteins deletion and the VP3 protein co-expression, named rPRV-XJ-ΔTK/gE/gI-VP3. The results revealed that PRV is a suitable viral live vector for VP3 protein expressing. As a vaccine, rPRV-XJ-ΔTK/gE/gI-VP3 is safe for mice, vaccination with it did not cause any clinical symptoms of PRV. Intranasal immunization with rPRV-XJ-ΔTK/gE/gI-VP3 induced strong cellular immune response and high levels of specific antibody against VP3 and gB and neutralizing antibodies against both PRV and SVA in mice. It provided 100% protection to mice against the challenge of virulent strain PRV-XJ, and alleviated the pathological lesion of heart and liver tissue in SVA infected mice. rPRV-XJ-ΔTK/gE/gI-VP3 appears to be a promising vaccine candidate against PRV and SVA for the control of the PRV variant and SVA.
Collapse
Affiliation(s)
- Qian Tao
- College of Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
| | - Lei Xu
- College of Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
| | - Yang Zhang
- College of Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
| | - Yanting Yang
- College of Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
| | - Zheyan Liu
- College of Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
| | - Tong Xu
- College of Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
| | - Siyuan Lai
- College of Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
| | - Yanru Ai
- College of Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China
| | - Ling Zhu
- College of Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China; Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu 611130, China.
| | - Zhiwen Xu
- College of Veterinary Medicine, Sichuan Agricultural University, Chengdu 611130, China; Key Laboratory of Animal Disease and Human Health of Sichuan Province, Chengdu 611130, China.
| |
Collapse
|
3
|
Vasconcelos JA, Mota AS, Olímpio F, Rosa PC, Damaceno-Rodrigues N, de Paula Vieira R, Taddei CR, Aimbire F. Lactobacillus rhamnosus Modulates Lung Inflammation and Mitigates Gut Dysbiosis in a Murine Model of Asthma-COPD Overlap Syndrome. Probiotics Antimicrob Proteins 2023:10.1007/s12602-023-10167-2. [PMID: 37837484 DOI: 10.1007/s12602-023-10167-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/18/2023] [Indexed: 10/16/2023]
Abstract
The asthma-COPD overlap syndrome (ACOS) presents lung inflammation similar to both asthma and chronic obstructive pulmonary disease (COPD). Due to the immune response between the lung and gut, it is possible that ACOS individuals present gut dysbiosis. Due to therapeutic limitations in ACOS, Lactobacillus rhamnosus (Lr) have received attention once Lr has been effective in asthma and COPD. However, there is no data about the Lr effect on both lung inflammation and gut dysbiosis in ACOS. Thus, our study investigated the Lr effect on lung inflammation, bronchoconstriction, airway remodeling, and gut dysbiosis in the murine ACOS model. Treated mice with Lr were exposed to HDM and cigarette smoke to induce ACOS. Sixty days after ACOS induction, mice were euthanized. Lung inflammation was evaluated in leukocytes in bronchoalveolar lavage fluid (BALF), airway remodeling, cytokine secretion, and transcription factor expression in the lung. The gut microbiota was assayed by 16S mRNA sequencing from a fecal sample. Leukocyte population, bronchial hyperreactivity, pro-inflammatory cytokines, and airway remodeling were attenuated in Lr-treated ACOS mice. Likewise, IL-4, IL-5, and IL-13, STAT6 and GATA3, as well as IL-17, IL-21, IL-22, STAT3, and RORɣt were reduced after Lr. In addition, IL-2, IL-12, IFN-γ, STAT1, and T-bet as well as IL-10, TGF-β, STAT5, and Foxp3 were restored after the Lr. Firmicutes was reduced, while Deferribacteres was increased after Lr. Likewise, Lr decreased Staphylococcus and increased Mucispirillum in ACOS mice. Lr improves fecal bacterial β-diversity. Our findings show for the first time the Lr effect on lung inflammation and gut dysbiosis in murine ACOS.
Collapse
Affiliation(s)
- Jéssica Aparecida Vasconcelos
- Department of Medicine, Postgraduate Program in Translational Medicine, Federal University of São Paulo (UNIFESP), Rua Pedro De Toledo, 720 - 2° Andar, Vila Clementino, 04039-002, Sao Paulo, SP, Brazil
- Lab. Immunopharmacology, Department of Science and Technology, Federal University of São Paulo (UNIFESP), Rua Talim, 330, Vila Nair, 12231-280, Sao Jose dos Campos, SP, Brazil
| | - Amanda Sodre Mota
- Department of Clinical and Toxicological Analyses - São Paulo, School of Pharmaceutical Sciences, University of São Paulo (USP), Avenida Professor Lineu Prestes, 580, Cidade Universitária, 05508-000, São Paulo, SP, Brazil
| | - Fabiana Olímpio
- Department of Medicine, Postgraduate Program in Translational Medicine, Federal University of São Paulo (UNIFESP), Rua Pedro De Toledo, 720 - 2° Andar, Vila Clementino, 04039-002, Sao Paulo, SP, Brazil
- Lab. Immunopharmacology, Department of Science and Technology, Federal University of São Paulo (UNIFESP), Rua Talim, 330, Vila Nair, 12231-280, Sao Jose dos Campos, SP, Brazil
| | - Paloma Cristina Rosa
- Department of Medicine, Postgraduate Program in Translational Medicine, Federal University of São Paulo (UNIFESP), Rua Pedro De Toledo, 720 - 2° Andar, Vila Clementino, 04039-002, Sao Paulo, SP, Brazil
- Lab. Immunopharmacology, Department of Science and Technology, Federal University of São Paulo (UNIFESP), Rua Talim, 330, Vila Nair, 12231-280, Sao Jose dos Campos, SP, Brazil
| | - Nilsa Damaceno-Rodrigues
- Laboratory of Cell Biology, Department of Pathology, School of Medicine, University of São Paulo (USP), São Paulo, São Paulo, Brazil
| | - Rodolfo de Paula Vieira
- Post-graduate Program in Human Movement and Rehabilitation and in Pharmaceutical Sciences, UniEvangelica, Avenida Universitária Km 3,5, Anapolis, GP, 75083-515, Brazil
| | - Carla Romano Taddei
- Department of Clinical and Toxicological Analyses - São Paulo, School of Pharmaceutical Sciences, University of São Paulo (USP), Avenida Professor Lineu Prestes, 580, Cidade Universitária, 05508-000, São Paulo, SP, Brazil
| | - Flavio Aimbire
- Department of Medicine, Postgraduate Program in Translational Medicine, Federal University of São Paulo (UNIFESP), Rua Pedro De Toledo, 720 - 2° Andar, Vila Clementino, 04039-002, Sao Paulo, SP, Brazil.
- Lab. Immunopharmacology, Department of Science and Technology, Federal University of São Paulo (UNIFESP), Rua Talim, 330, Vila Nair, 12231-280, Sao Jose dos Campos, SP, Brazil.
| |
Collapse
|